Hinge Health/$HNGE
1D1W1MYTD1Y5YMAX
Capital at risk
About Hinge Health
Hinge Health Inc is a technology platform for individuals seeking to treat and prevent joint and muscle pain. Through a combination of AI-powered motion tracking technology, the Company's platform helps members address chronic musculoskeletal (MSK) conditions, enables improved member outcomes and supports cost reductions for its clients.
- Ticker
- $HNGE
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 1,437
- Headquarters
- San Francisco, United States
- Website
- www.hingehealth.com
Hinge Health Metrics
BasicAdvanced
$7.6B
70.21
$1.34
-
-
Price and volume
Market cap
$7.6B
52-week high
$95.62
52-week low
$30.08
Average daily volume
1.9M
Financial strength
Current ratio
1.336
Quick ratio
1.069
Long term debt to equity
0.005
Total debt to equity
0.017
Profitability
EBITDA (TTM)
95.694
Gross margin (TTM)
84.54%
Net profit margin (TTM)
15.15%
Operating margin (TTM)
12.75%
Effective tax rate (TTM)
1.69%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
7.70%
Return on equity (TTM)
30.38%
Valuation
Price to earnings (TTM)
70.208
Price to revenue (TTM)
10.268
Price to book
21.83
Price to tangible book (TTM)
27.02
Price to free cash flow (TTM)
26.04
Free cash flow yield (TTM)
3.84%
Free cash flow per share (TTM)
3.599
Growth
Revenue change (TTM)
49.76%
Earnings per share change (TTM)
-106.77%
What the Analysts think about Hinge Health
Analyst ratings (Buy, Hold, Sell) for Hinge Health stock.
Analyst projections of the future price of Hinge Health stock.
Bulls say / Bears say
Hinge Health reported Q2 2026 revenue of $212.82 million, up 53% year-over-year and surpassing the $201.03 million consensus, underlining strong platform adoption and robust member demand (Reuters)
Management raised full-year 2026 revenue guidance to $856 million–$860 million, reflecting confidence in continued membership and client growth momentum (Reuters)
Hinge Health signed a definitive agreement to acquire Cylinder Health for $105 million, expanding into the $135 billion gastrointestinal care market and broadening its specialty care offerings (Reuters)
The $105 million acquisition of Cylinder Health will not generate revenue until the integrated Gastrointestinal Care Program launches in 2027, introducing near-term execution and integration risks without immediate financial benefits (Reuters)
Revenue is heavily concentrated among self-insured U.S. employers and the five largest national health plans by self-insured lives, creating client concentration risk and potential volatility if major corporate or health plan clients reduce benefits spending (SEC 10-K 2025)
Significant stock-based compensation—totaling $19.1 million in Q2 2026—and past GAAP net losses of $575.7 million in Q2 2025 underscore volatile earnings and potential dilution, which may cloud corporate profitability despite non-GAAP adjustments (Hinge Health IR)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Hinge Health Financial Performance
Revenues and expenses
Hinge Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Hinge Health News
AllArticlesVideos
Funds containing Hinge Health
AllEURUSDGBP
Fund name | Fund size | $HNGE weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.13% |
iShares MSCI World Small Cap$WSML | $9B | 0.04% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.